Physician profile
Gary Eden
NPI 1316903990
$2,391.62
in general payments reported to CMS, 2019-2025
32 companies · $279 in 2025
The $279 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $400 · 2020: $157 · 2021: $259 · 2022: $238 · 2023: $520 · 2024: $539 · 2025: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,263 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,263.23 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $296.32 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $290.13 | 2019-2025 | Enhertu |
| Endomagnetics Ltd | $195.75 | 2023 | Magtrace, Magseed |
| Hologic INC | $185.80 | 2019-2022 | |
| Daiichi Sankyo INC. | $157.70 | 2022-2025 | Enhertu |
| Abbvie INC. | $143.43 | 2019-2023 | Venclexta |
| Davol INC. | $136.63 | 2025 | Arista |
| Janssen Biotech, INC. | $104.15 | 2019-2025 | Rybrevant, Darzalex |
| Genzyme Corporation | $85.83 | 2019-2021 | |
| Genmab U.S., INC. | $81.54 | 2024 | Epkinly |
| Seagen INC. | $63.23 | 2021-2023 | Padcev, Adcetris |
| Genentech USA, INC. | $58.18 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $57.48 | 2023-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Puma Biotechnology, INC. | $52.61 | 2019-2020 | |
| Eisai INC. | $44.58 | 2023-2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aveo Pharmaceuticals, INC. | $38.19 | 2022-2023 | Fotivda |
| Sun Pharmaceutical Industries INC. | $36.86 | 2024 | |
| Pfizer INC. | $36.64 | 2022-2023 | |
| Incyte Corporation | $35.22 | 2019-2024 | Pemazyre, Monjuvi, Jakafi |
| Amgen INC. | $35.15 | 2020-2023 | Lumakras |
| Celgene Corporation | $34.46 | 2019-2020 | |
| Blueprint Medicines Corporation | $32.14 | 2025 | Ayvakit |
| Ipsen Biopharmaceuticals, INC | $29.09 | 2019-2024 | Onivyde |
| Lilly USA, LLC | $26.30 | 2021-2024 | Verzenio |
| Myovant Sciences INC. | $21.85 | 2022 | |
| Recordati_rare_diseases_inc. | $20.49 | 2025 | Enjaymo |
| Beigene USA, INC. | $19.39 | 2024 | Brukinsa |
| Takeda Pharmaceuticals U.S.A., INC. | $19.26 | 2024 | Alunbrig |
| Bayer Healthcare Pharmaceuticals INC. | $16.62 | 2020 | |
| Astellas Pharma US INC | $14.70 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $12.53 | 2019 | |
| Rigel Pharmaceuticals, INC. | $9.37 | 2023 | Tavalisse, Rezlidhia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Eden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.